376 related articles for article (PubMed ID: 23980523)
1. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
[TBL] [Abstract][Full Text] [Related]
2. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
Molina JM; Clumeck N; Redant K; Rimsky L; Vanveggel S; Stevens M;
AIDS; 2013 Mar; 27(6):889-897. PubMed ID: 23276806
[TBL] [Abstract][Full Text] [Related]
4. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
5. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
6. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
7. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Rimsky L; Vingerhoets J; Van Eygen V; Eron J; Clotet B; Hoogstoel A; Boven K; Picchio G
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):39-46. PubMed ID: 22067667
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
[TBL] [Abstract][Full Text] [Related]
10. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
[TBL] [Abstract][Full Text] [Related]
12. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
[TBL] [Abstract][Full Text] [Related]
13. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
Imaz A; Podzamczer D
AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
[TBL] [Abstract][Full Text] [Related]
14. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
[TBL] [Abstract][Full Text] [Related]
16. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
Cohen CJ; Molina JM; Cassetti I; Chetchotisakd P; Lazzarin A; Orkin C; Rhame F; Stellbrink HJ; Li T; Crauwels H; Rimsky L; Vanveggel S; Williams P; Boven K;
AIDS; 2013 Mar; 27(6):939-950. PubMed ID: 23211772
[TBL] [Abstract][Full Text] [Related]
17. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
Wilkin A; Pozniak AL; Morales-Ramirez J; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K;
AIDS Res Hum Retroviruses; 2012 May; 28(5):437-46. PubMed ID: 21902621
[TBL] [Abstract][Full Text] [Related]
19. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.
Li SL; Xu P; Zhang L; Sun GX; Lu ZJ
HIV Clin Trials; 2014; 15(6):261-8. PubMed ID: 25433665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
